Upstream Bio, Inc. (UPB)
NASDAQ: UPB · Real-Time Price · USD
4.690
-0.160 (-3.30%)
Oct 6, 2026, 10:44 AM EDT - Market open
Upstream Bio Employees
Upstream Bio had 75 employees as of December 31, 2025. The number of employees increased by 23 or 44.23% compared to the previous year.
Employees
75
Change (1Y)
23
Growth (1Y)
44.23%
Revenue / Employee
$42,107
Profits / Employee
-$2,086,667
Market Cap
256.88M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 75 | 23 | 44.23% |
| Dec 31, 2024 | 52 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| EyePoint | 214 |
| AC Immune | 122 |
| Zentalis Pharmaceuticals | 106 |
| Century Therapeutics | 78 |
| Immuneering | 57 |
| Pyxis Oncology | 56 |
| Camp4 Therapeutics | 48 |
UPB News
- 14 days ago - These beaten-down stocks could bounce back in January, if history is any guide - Market Watch
- 4 weeks ago - Upstream Bio presents results from VALIANT trial at ERS Congress - TheFly
- 4 weeks ago - Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026 - GlobeNewsWire
- 5 weeks ago - Upstream Bio unveils Phase 3 plans for Verekitug in asthma, nasal polyps - TheFly
- 5 weeks ago - Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP - GlobeNewsWire
- 7 weeks ago - Upstream Bio price target lowered to $25 from $43 at Truist - TheFly
- 7 weeks ago - Upstream Bio price target raised to $9 from $8 at JPMorgan - TheFly
- 7 weeks ago - Upstream Bio price target lowered to $25 from $43 at Truist - TheFly